#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Spinal cord injury cervical Thalassaemia alpha Asthma Thymic carcinoma Vascular malformation Hairy cell leukaemia recurrent Testicular leiomyosarcoma Glioblastoma multiforme Acute graft versus host disease Corneal neovascularisation Haematological malignancy Neuroendocrine carcinoma metastatic Bronchopulmonary dysplasia Renal cancer metastatic Microvillous inclusion disease More trials…

    Learn about Rare Diseases

    Andersen-Tawil syndrome – Treatment Haemophilia B with anti factor IX – Diagnostics Breast angiosarcoma – Basic Information Short-bowel syndrome – Trials in Disease Marginal zone lymphoma refractory – Trials in Disease Krabbe’s disease – Diagnostics Leiomyosarcoma – Treatment Mantle cell lymphoma stage III – Basic Information Hereditary hypophosphataemic rickets – Life with Disease Angiosarcoma non-metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Diltiazem Tolebrutinib PF-07868489 Hexaminolevulinate Pervi-Fus Rifapentine Fluoroethyltyrosine F-18 Chlorhexidine Dihydrochloride Lazertinib Ioflupane (123I) Vilobelimab Zanidatamab Allo-501A Agrostis Stolonifera Pollen Tenecteplase Montelukast Sodium Pf-06480605 Gt005 Nortriptyline Vib1116 More therapies…

    Learn about Your Condition

    Colon cancer stage III Crohn's disease Head and neck cancer stage III Morning sickness Hyperkalaemia Immunodeficiency Cutibacterium acnes infection Inner ear disorder Hypochondroplasia Electronic cigarette user Renal cancer recurrent Fibrosarcoma metastatic Depression Oesophageal carcinoma Familial hypertriglyceridaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Pembrolizumab
    Belgium France Germany Italy Poland Spain

  • Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Igg4 Tetravalent Bispecific Antibody-Like Protein Against Pd-1 And Ctla4
    • Dexamethasone
    • Docetaxel
    Belgium Bulgaria France Poland Spain

  • Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

    Not recruiting

    3 1
    Investigated Drugs:
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Finland +14

  • Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Tiragolumab
    Belgium France Germany Italy Poland Spain

  • Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Bulgaria Croatia Czechia Finland +12

  • Study on Spesolimab for Treating Recurrent Flares in Patients with Generalized Pustular Psoriasis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Spesolimab
    Belgium France Germany Italy Spain

  • Study on the Effectiveness and Safety of LYR-210 and Dexamethasone for Treating Chronic Sinusitis in Adults Without Nasal Polyps

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic sinusitis
    Investigated Drugs:
    • Mometasone Furoate
    • Dexamethasone
    Belgium Bulgaria Germany Hungary Poland

  • Study of BMS-986449 and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Bms-986449-03
    • Nivolumab
    Belgium France Italy The Netherlands Spain

  • Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Apalutamide
    • Bicalutamide
    • Other Hormone Antagonists And Related Agents
    Belgium Czechia France Germany Italy Poland +3

  • Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Lenvatinib
    • Paclitaxel
    Austria Belgium Germany Ireland Italy Poland +1
Previous Page
1 … 55 56 57 58 59 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!